ABSTRACT
Objectives To estimate the effect that summer school holidays had on the growth rate in Sars-CoV-2 infections across German districts. The Robert-Koch-Institute reports that during the summer holiday period a foreign country is stated as the most likely place of infection for an average of 27 and a maximum of 49 percent of new Sars-CoV-2 infections in Germany. Yet, infection may have taken place elsewhere, not all international travel is holiday-related and any impact of holiday-related travel will not be restricted to holidays abroad.
Design Cross-sectional study on observational data. In Germany, summer school holidays are coordinated between states and spread out over 13 weeks. We analyse the association between these holidays and the weekly infection growth rate in SARS-CoV-2 infections across 401 German districts. Employing a dynamic model with district fixed effects, we test whether the holiday season results in a statistically significantly higher infection growth rate than the period of two weeks before holidays start, our presumed counterfactual.
Results We find effects of the holiday period equal in size to almost 50 percent of the average district growth rate in new infections in Germany during their respective final week of holidays and the two weeks after holidays end. States in the West of Germany tend to experience stronger effects than those in the East. This is consistent with another result, namely that we find statistically significant interaction effects of school holidays with per capita taxable income and the share of foreign residents in a district’s population, with both factors hypothesised to increase holiday-related travels.
Conclusions Our results suggest that changed behaviour during the holiday season accelerated the pandemic and made it considerably more difficult for public health authorities to contain the spread of the virus by means of contact tracing. Governments did not prepare adequately or timely for this acceleration.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n.a.
Funding Statement
No external funding supported the work on this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n.a.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
thomas.pluemper{at}wu.ac.at
e.neumayer{at}lse.ac.uk
The manuscript has been revised throughout. Data and analyses have been updated.
Data Availability
Replication data will be published on dataverse.com.
